What question did this study set out to answer?

The aim is to develop a personalized MRD detection method using droplet digital PCR for acute myeloid leukemia driven by gene fusions.

Personalized Fusion Measurable Residual Disease Detection in Acute Myeloid Leukemia Using ddPCR

View Full Paper

Ask AI

Bookmark

Authors

Personalized ddPCR detects MRD in acute myeloid leukemia, suggesting improved therapy selection and patient outcomes.

The aim is to develop a personalized MRD detection method using droplet digital PCR for acute myeloid leukemia driven by gene fusions.
Developed personalized MRD assays from diagnostic sequencing of unique gene fusions.
Validated assays to a limit of detection of 1 in 100,000.
Analyzed 155 patient specimens from diverse gene fusions during diagnosis, treatment, and surveillance.
Identified disease recurrence in eight patients 38-103 days prior to standard MPFC testing.
All patients with increasing fusion burden subsequently experienced relapse.
Non-invasive peripheral blood sampling showed similar fusion transcript abundance to bone marrow, indicating replacement potential.

Noor et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark